Summary & Overview
HCPCS J1675: Histrelin Acetate Injection, 10 micrograms
HCPCS Level II code J1675 denotes an injectable dose of histrelin acetate, 10 micrograms. Histrelin acetate is used in clinical settings that require hormonal suppression therapies; billing for this drug captures the supply and administration of a specific microgram dose. Nationally, accurate coding for injectable pharmaceuticals like J1675 matters for clinical documentation, appropriate coverage decision-making, and consistent reimbursement across payers.
Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find context on clinical use and typical sites of service, plus an explanation of what the code represents. The publication provides benchmarks and policy-related summaries relevant to reimbursement and coverage trends, clarifies billing elements tied to injectable drug services, and outlines typical administrative considerations for outpatient delivery of this medication.
This summary is intended for revenue cycle professionals, clinicians who order or administer injectable therapies, and policy analysts seeking concise information about J1675 and its role in outpatient injectable drug billing.
Billing Code Overview
HCPCS Level II code J1675 represents an injectable formulation: histrelin acetate, 10 micrograms. The service type is drug administration (injectable medication), typically delivered as an injection by a clinician. The typical site of service for this medication is outpatient settings where injectable therapies are provided, including physician offices, clinics, and outpatient infusion or procedure areas.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with advanced prostate cancer or central precocious puberty presents for outpatient administration of a long‑acting gonadotropin‑releasing hormone (GnRH) agonist implant. The billed item J1675 (injection, histrelin acetate, 10 micrograms) is typically used when a clinician inserts a subcutaneous histrelin implant or administers the histrelin acetate preparation as part of a hormone‑suppression regimen. The usual workflow begins with a specialty clinic visit (urology, pediatric endocrinology, or medical oncology) where diagnosis, therapy goals, and informed consent are documented. The patient is scheduled for the implantation or injection in an ambulatory surgery center, clinic procedure room, or infusion suite depending on setting and payer rules. On the day of service, pre‑procedure verification, medication reconciliation, sedation or local anesthesia as indicated, and the sterile procedure are performed. The provider documents implant lot number, site of insertion (commonly subdermal upper arm or abdomen), and patient education about expected effects and follow‑up. Post‑procedure monitoring occurs for immediate complications and instructions are given for long‑term monitoring of testosterone/estrogen levels or growth parameters in pediatric patients. Billing uses J1675 for the drug, and appropriate CPT and evaluation codes are reported for the insertion procedure and any anesthesia or monitoring services.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|